N816 Anti-TNF therapy improves the quality of life in patients with ulcerative colitis

Silva, R.P.L.; Baima, Júlio Pinheiro; Bissoli, G.C.; Farinelli, Elen; Síbia, Carina; Barros, Jaqueline Ribeiro de; Biondi, R.; Renosto, Fernanda Lofiego; Hossne, Rogério Saad; Sassaki, Lígia Yukie

doi:10.1093/ecco-jcc/jjx002.940

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients on infliximab maintenance therapy kept this HRQoL improvement at weeks 30 and 54, also observed on the SF-36 score [ 33 ]. Recently, it has been shown that infliximab still improves UC patients’ HRQoL in a prospective study in which a significant change of IBDQ score was seen from 116.20 at baseline to 176.62 at week 54 ( p = 0.02) [ 34 ].…”

Section: Quality Of Life Studies In Ucmentioning

confidence: 99%

Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment

Calviño-Suárez

Ferreiro-Iglesias

Baston‐Rey

et al. 2021

IJERPH

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are chronic disabling conditions, characterized by an unpredictable course with flare-ups and periods of remission, that frequently affect young people and require lifelong medical follow-up and treatment. For years, the main endpoints of IBD treatment had been clinical remission and response, followed by biomarker normalization and mucosal healing. In the last decades, different therapies have been proved to be effective to treat IBD and the use of patient reported outcome (PRO) have become more relevant. Therefore, health-related quality of life (HRQoL) that has been defined as the value assigned to the duration of life influenced by physical and mental health, has been suggested as an important endpoint for IBD management since multiple studies have shown that IBD impairs it, both physically and psychologically. Thus, HRQoL has been included as an outcome in numerous studies evaluating different IBD therapies, both clinical trials and real-life studies. It has been assessed by using both generic and specific disease tools, and most treatments used in clinical practice have been demonstrated to improve HRQoL. The relevance of HRQoL as an endpoint for new drugs is going to increase and its management and improvement will also improve the prognosis of IBD patients.

show abstract

Section: Quality Of Life Studies In Ucmentioning

confidence: 99%

Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment

Calviño-Suárez

Ferreiro-Iglesias

Baston‐Rey

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…However, these medications and advanced therapies [e.g., tumor necrosis factor inhibitors (TNFi), non-TNFi, and Janus kinase inhibitors (JAKi)]) provide symptomatic relief and can result in healing of the inflamed intestine in CD or UC conditions [ 16 , 17 ]. Use of advanced therapies such as TNFi and JAKi have improved the health-related QoL in patients with IBD by decreasing symptomatology associated with hospital admissions and reducing side effects experienced from the use of other conventional therapies [ 18 – 20 ]. Although advanced therapies have been shown to achieve clinical response in patients with CD or UC, their role in reducing the use of other pain medications to alleviate pain symptoms in IBD remains poorly understood.…”

Section: Introductionmentioning

confidence: 99%

Medication use among patients with Crohn’s disease or ulcerative colitis before and after the initiation of advanced therapy

et al. 2022

View full text Add to dashboard Cite

Background Although various treatments help reduce abdominal pain, real-world pain medication utilization among patients with Crohn’s disease (CD) or ulcerative colitis (UC) receiving advanced therapies is poorly understood. The aim is to understand the utilization of pain medication 12 months before and after the initiation of advanced therapies among patients with newly diagnosed CD or UC. Methods This retrospective, observational cohort study used administrative medical and pharmacy claims data of patients with CD or UC from HealthCore Integrated Research Database (HIRD®). The data from patients with use of pain medication over 12 months follow-up (after the initiation date of advanced therapies) were collected and analyzed. Differences in the use of pain medication 12 months before and after the initiation of advanced therapies were assessed using McNemar's and Wilcoxon signed-rank test. Results Prior to initiating advanced therapies, 23.1% of patients with CD (N = 540) received nonsteroidal anti-inflammatory drugs (NSAIDs), 78.1% glucocorticoids, 49.4% opioids, and 29.3% neuromodulators; similarly, 20.9% of patients with UC (N = 373) received NSAIDs, 91.4% glucocorticoids, 40.8% opioids, and 29.5% neuromodulators. After receiving advanced therapies for 12 months, patients reported a reduction in the use of steroids (78.1% vs. 58.9%, P < 0.001 in CD; 91.4% vs. 74.3%, P < 0.001 in UC), opioids (49.4% vs. 41.5%, P = 0.004 in CD; 40.8% vs. 36.5%, P = 0.194 in UC), and NSAIDs (23.1% vs. 15.0%, P < 0.001 in CD; 20.9% vs. 15.8%, P = 0.035 in UC), while the use of neuromodulators significantly increased (29.3% vs. 33.7%, P = 0.007 in CD; 29.5% vs. 35.7%; P = 0.006 in UC). Conclusions The use of pain medications such as NSAIDs, glucocorticoids, opioids, and neuromodulators was common among patients with CD or UC. These results highlight that patients with CD or UC continued to receive pain medications even after initiating advanced therapies.

show abstract

N816 Anti-TNF therapy improves the quality of life in patients with ulcerative colitis

Cited by 2 publications

References 0 publications

Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment

Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment

Medication use among patients with Crohn’s disease or ulcerative colitis before and after the initiation of advanced therapy

Contact Info

Product

Resources

About